.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Chubb
Johnson and Johnson
US Department of Justice
Daiichi Sankyo
QuintilesIMS
Teva
Fish and Richardson
McKinsey
Farmers Insurance

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091542

« Back to Dashboard
NDA 091542 describes TOPOTECAN HYDROCHLORIDE, which is a drug marketed by Sun Pharm Inds Ltd, Accord Hlthcare, Actavis Totowa, Mylan Labs Ltd, Teva Pharms Usa, Novast Labs Ltd, Hong Kong, Fresenius Kabi Oncol, Hospira Inc, Sagent Pharms, Fresenius Kabi Usa, Dr Reddys Labs Ltd, and Cipla Ltd, and is included in fourteen NDAs. It is available from eleven suppliers. Additional details are available on the TOPOTECAN HYDROCHLORIDE profile page.

The generic ingredient in TOPOTECAN HYDROCHLORIDE is topotecan hydrochloride. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.

Summary for 091542

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 091542

Mechanism of ActionTopoisomerase Inhibitors

Medical Subject Heading (MeSH) Categories for 091542

Suppliers and Packaging for NDA: 091542

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION 091542 ANDA Pfizer Laboratories Div Pfizer Inc. 0069-0075 0069-0075-01 4 mL in 1 VIAL (0069-0075-01)
TOPOTECAN HYDROCHLORIDE
topotecan hydrochloride
INJECTABLE;INJECTION 091542 ANDA Mylan Institutional LLC 67457-474 67457-474-04 1 VIAL in 1 CARTON (67457-474-04) > 4 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 4MG BASE/VIAL
Approval Date:Aug 28, 2012TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
US Department of Justice
Johnson and Johnson
McKinsey
Queensland Health
Express Scripts
Cipla
Moodys
Julphar
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot